Should clinicians be extra vigilant when deciding who receives antiviral therapy, or are the adverse effects few and infrequent?
Desirae Lindquist, PharmD, BCPS
Advertisement
Articles by Desirae Lindquist, PharmD, BCPS
Advertisement
Latest Updated Articles
- Risks Associated With Direct-Acting Antivirals—Smoke or Fire?
Published: May 9th 2017 | Updated:
Advertisement
Advertisement
Trending on Contagion Live
1
Phase 3 Trial Confirms Superior Efficacy of Oral Pritelivir for Refractory HSV in Immunocompromised Patients
2
Top Infectious Disease News Stories Week of October 11-October 17
3
Invivyd Announces FDA Clearance of IND Application for VYD2311 and Advancement of REVOLUTION Clinical Program
4
